A botulinum toxin-type formula developed by a local pharmaceutical company is reportedly more effective than existing products in smoothing out wrinkles.
Kim Bum-joon, professor at the Department of Dermatology at Chung-Ang University Hospital, injected either Botox or Nabota into 268 patients to treat wrinkles at the indentation between the bridge of the nose and the forehead. Nabota is a new botulinum toxin formula developed by a local drug maker. The clinical trial was done in collaboration with Asan Medical Center and St. Paul's Hospital of Catholic University.
Four weeks later, patents that were injected with the new botulinum toxin-type formula showed that their skin contracted up to 93.9 percent, higher than the 88.6 percent shown by those who used Botox. Moreover, no adverse drug reactions were reported, which proved that the new drug is stable and effective in treating wrinkles.
Botulinum toxin type A is substance that prevents muscles from contracting by blocking the secretion of a neurotransmitter called acetyl choline. Botox, developed by U.S. pharmaceutical company Allergan, has been widely used for cosmetic purposes, after it was approved by the U.S. Food and Drug Administration in 2002 to relax muscles to get rid wrinkles. Nabota is a botulinum toxin formula with higher purity developed by Daewoong Pharmaceutical through its purification process.
The research findings are going to be published online in the upcoming issue of International Journal of Dermatology, a monthly scientific journal published by Wiley.